Comparative Evaluation of Melatonin Versus MTA on Vital Pulp Therapy in Young Permanent First Molars: An in Vivo Study
Launched by SUEZ CANAL UNIVERSITY · Apr 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining the effectiveness of melatonin compared to a substance called MTA (Mineral Trioxide Aggregate) in treating dental issues in children, specifically focusing on young permanent first molars that are still healthy and restorable. The main purpose is to see how these two treatments can help maintain the vitality of the tooth pulp, which is the soft tissue inside the tooth.
To be eligible for this study, children must be between the ages of 6 and 8 years old and in good health. They should have specific dental conditions, such as having young permanent first molars that can still be treated without any signs of severe problems like pain, swelling, or infection. If your child qualifies and decides to participate, they will receive either melatonin or MTA as part of their dental care. This study is currently looking for participants, and it aims to provide valuable insights into better dental treatments for children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * 1- Apparently healthy and medically free children. 2- Their age ranges from 6-8 years. 3- Both boys and girls will be included. 4- Children should have mandibular permanent first molars with the following clinical and radiographic criteria. 4.1Restorable young permanent first molars. 4.2Absence of clinical evidence of pulp degeneration:
- • No history of spontaneous pain, history of night pain or pain that not relieved by analgesics.
- • No pain on percussion.
- • No mobility.
- • Absence of abscess, purulent sinus or soft tissue edema.
- • Bleeding should stop within 5 minutes after the amputated pulp stumps.
- Exclusion Criteria:
- • Internal root resorption.
- • External root resorption.
- • Inter radicular or periapical bone destruction (radiolucency)
- • A deep carious lesion radiologically that approaches the pulp
About Suez Canal University
Suez Canal University is a distinguished academic institution dedicated to advancing medical research and education in the region. As a clinical trial sponsor, the university focuses on conducting innovative studies that aim to enhance patient care and outcomes. Leveraging its strong network of healthcare professionals and state-of-the-art facilities, Suez Canal University fosters collaboration between researchers and clinicians to explore new therapeutic approaches and validate clinical practices. Committed to ethical standards and scientific rigor, the university plays a pivotal role in contributing to the global body of medical knowledge and improving healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ismailia, , Egypt
Patients applied
Trial Officials
Gihan GED El-Desouky, Professor
Principal Investigator
Professor
Ghada AH Elbaz, Professor
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported